Adam Gregory

Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.

C. Brander, V. Miller, T. Peto, 2021, Cell reports.

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

Rebecca M. Baker, Phuong Thi Tuyet Nguyen, Carol L. Eyler, 2021, The Lancet Infectious Diseases.

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis

Calliope A. Dendrou, G. McVean, M. Mann, 2012, Nature.

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

M. Johnson, V. Miller, T. Peto, 2020, The Lancet.

Incoming HIV Virion-Derived Gag Spacer Peptide 2 (p1) is a Target of Effective CD8+ T Cell Antiviral Responses

C. Brander, V. Miller, T. Peto, 2020, SSRN Electronic Journal.